Pharmafile Logo
Pharmafocus logo
Advanced Search

Spravato

Showing 8 posts of 8 posts found.

spravato

Janssen’s esketamine nasal spray secures CHMP recommendation in Europe for the rapid reduction of depressive symptoms in a psychiatric emergency for patients with major depressive disorder

December 11, 2020
Medical Communications EMA, Europe, Spravato, depression

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has moved to recommend Janssen’s …

News

NICE knocks back Janssen’s Spravato nasal spray for the second time in treatment-resistant depression

September 3, 2020
Sales and Marketing Janssen, Spravato, depression, pharma

NICE has opted to reject Janssen’s nasal spray Spravato (esketamine) for routine use on the NHS for treatment-resistant major depressive …

News
janssen_latest_logo_on_sign

FDA expands approval for Janssen’s Spravato nasal spray to cover major depressive disorder with suicidal ideation

August 4, 2020
Manufacturing and Production FDA Janssen, Spravato, depression

The FDA has moved to expand the existing approval of Janssen’s Spravato (esketamine) CIII nasal spray to include treatment of symptoms …

News
janssen_latest_logo_on_sign

NICE rejects Janssen’s esketamine nasal spray Spravato for treatment-resistant depression

January 28, 2020
Manufacturing and Production, Sales and Marketing Janssen, NHS, NICE, Spravato, depression

Janssen’s Spravato (esketamine) nasal spray, derived from the party drug ketamine, has been turned down by NICE for NHS use …

News
spravato

New Phase 3 data backs up the efficacy of esketamine in treatment-resistant depression

May 21, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Spravato, depression, esketamine, pharma

New research has been published on the efficacy of esketamine in the treatment of depression, following its approval from the …

News
5789851635_d493d41b35_z

Department of Veteran Affairs to offer Janssen’s esketamine to veterans with depression

March 21, 2019
Medical Communications Jannsen, Spravato, VA, depression, esketamine, military, veteran affairs

The United States Department of Veteran Affairs (VA), the federal agency responsible for providing healthcare services to military veterans, is …

News
spravato

Janssen’s party drug-based nasal spray becomes first new FDA-approved depression treatment in 30 years

March 6, 2019
Research and Development, Sales and Marketing Janssen, Spravato, depression, esketamine, pharma

The field of depression therapy has seen its biggest leap forward in over three decades, the FDA approval of Janssen’s …

News
janssen_latest_logo_on_sign_closer

Janssen’s esketamine drug recommended by FDA panel for depression

February 13, 2019
Research and Development, Sales and Marketing FDA, Janssen, Spravato, depression, esketamine, major depressive disorder, pharma

In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024